Jiangsu Hengrui Pharmaceuticals Publishes 2025 Audited Annual Results

An update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) is now available.

Jiangsu Hengrui Pharmaceuticals has released its audited annual results for the year ended 31 December 2025, making its full 2025 annual report available to investors and the public via the Hong Kong stock exchange website and the company’s own site. The announcement formalizes the disclosure of the group’s financial performance and governance information, underlining ongoing compliance with Hong Kong listing rules and providing stakeholders with detailed data to assess the company’s operations and board composition.

The board, chaired by Mr. Sun Piaoyang, confirmed the report’s publication and listed the current mix of executive, non-executive and independent non-executive directors overseeing the company. By setting out the structure of its leadership and the sections covered in the annual report, the company highlights its corporate governance framework and offers greater transparency to shareholders and regulators for the latest financial year.

The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.

More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company listed in Hong Kong under stock code 1276. It operates through multiple subsidiaries and focuses on developing, manufacturing and marketing pharmaceutical products, positioning itself as a significant player in the Chinese healthcare and drug markets.

Average Trading Volume: 2,600,925

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$403B

For a thorough assessment of 1276 stock, go to TipRanks’ Stock Analysis page.